Search

Displaying results 3351 - 3360 of 6076 in total
  1. Drug

    Combretastatin

    go.drugbank.com/drugs/DB12596
    Investigational

    Combretastatin has been investigated for the treatment of Anaplastic Thyroid Cancer.

  2. Drug

    D-Leucine

    go.drugbank.com/drugs/DB01746
    Experimental

    An essential branched-chain amino acid important for hemoglobin formation. [PubChem]

  3. Drug

    Bunamidine

    go.drugbank.com/drugs/DB11501
    ExperimentalVet approved

    Bunamidine is a veterinary anti-platyhelmintic agent used for taenia infestations.

  4. Drug

    Belotecan

    go.drugbank.com/drugs/DB12459
    Investigational

    Belotecan has been investigated for the treatment of Epithelial Ovarian Cancer.

  5. Drug

    ROX-888

    go.drugbank.com/drugs/DB05364
    Experimental

    ROX-888 is ROXRO's lead compound which is currently in Phase 3 trials for the treatment of acute pain, including post-operative pain.

  6. Drug

    Potassium sulfate

    go.drugbank.com/drugs/DB14499
    Approved

  7. Drug

    Aplaviroc

    go.drugbank.com/drugs/DB06497
    Investigational

    A spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1.

  8. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    Protirelin is the pharmaceutically available synthetic analogue of the endogenous peptide thyrotropin-releasing hormone (TRH). It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimu...

    Categories: Tests for Thyreoidea Function
  9. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin se...

  10. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System